2 results
Approved WMOCompleted
The purpose of the study is to investigate how well LY2165766 is tolerated, and to investigate whether LY2165766 administration is associated with body weight gain in comparison to placebo. Olanzapine is included in this study as a positive control…
Approved WMORecruiting
ALZ-801 is an oral agent that is being developed as a potential disease modifying treatment for AD. This 78-week Phase 3 study will focus on Early AD subjects who carry the APOE4/4 genotype, and is designed according to current regulatory guidance…